Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Yesterday, April 15, 2015, 48 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $81.85 to $422,748,916.10.

Highlighted Stocks Traded by Insiders:

InvenSense (INVN) - FREE Research Report

Lloyd Stephen, who is VP Engineering & New Product at InvenSense, sold 6,000 shares at $16.33 on April 15, 2015. Following this transaction, the VP Engineering & New Product owned 30,336 shares meaning that the stake was reduced by 16.51% with the 6,000-share transaction.

The shares most recently traded at $16.30, down $0.03, or 0.16% since the insider transaction. Historical insider transactions for InvenSense go as follows:

  • 4-Week # shares sold: 6,000
  • 12-Week # shares sold: 15,649
  • 24-Week # shares sold: 15,649

The average volume for InvenSense has been 1.5 million shares per day over the past 30 days. InvenSense has a market cap of $1.5 billion and is part of the technology sector and electronics industry. Shares are up 0.31% year-to-date as of the close of trading on Wednesday.

InvenSense, Inc. designs, develops, markets, and sells micro-electro-mechanical system (MEMS) gyroscopes for motion tracking devices in consumer electronics. Currently, there are 6 analysts who rate InvenSense a buy, no analysts rate it a sell, and 5 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on INVN - FREE

TheStreet Quant Ratings rates InvenSense as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and increase in net income. However, as a counter to these strengths, we also find weaknesses including disappointing return on equity and a generally disappointing performance in the stock itself. Get the full InvenSense Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

PetMed Express (PETS) - FREE Research Report

Rosenbloom Bruce S, who is Chief Financial Officer at PetMed Express, sold 500 shares at $16.75 on April 15, 2015. Following this transaction, the Chief Financial Officer owned 44,517 shares meaning that the stake was reduced by 1.11% with the 500-share transaction.

Akdag Menderes, who is CEO & President at PetMed Express, sold 7,499 shares at $16.75 on April 15, 2015. Following this transaction, the CEO & President owned 538,000 shares meaning that the stake was reduced by 1.37% with the 7,499-share transaction.

The shares most recently traded at $16.91, up $0.16, or 0.95% since the insider transaction. Historical insider transactions for PetMed Express go as follows:

  • 4-Week # shares sold: 17,501
  • 12-Week # shares sold: 18,001
  • 24-Week # shares sold: 80,668

The average volume for PetMed Express has been 235,400 shares per day over the past 30 days. PetMed Express has a market cap of $341.2 million and is part of the health care sector and drugs industry. Shares are up 17.47% year-to-date as of the close of trading on Wednesday.

PetMed Express, Inc. and its subsidiaries, doing business as 1-800-PetMeds, operates as a pet pharmacy in the United States. The company markets prescription and non-prescription pet medications, health products, and supplies for dogs and cats. The stock currently has a dividend yield of 4.04%. The company has a P/E ratio of 19.8. Currently, there are no analysts who rate PetMed Express a buy, 2 analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on PETS - FREE

TheStreet Quant Ratings rates PetMed Express as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, increase in net income, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels and good cash flow from operations. We feel these strengths outweigh the fact that the company shows low profit margins. Get the full PetMed Express Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Ladenburg Thalmann Financial Services (LTS) - FREE Research Report

Giovanniello joseph, who is Senior Vice President at Ladenburg Thalmann Financial Services, bought 2,000 shares at $3.73 on April 15, 2015. Following this transaction, the Senior Vice President owned 180,013 shares meaning that the stake was boosted by 1.12% with the 2,000-share transaction.

The shares most recently traded at $3.57, down $0.16, or 4.58% since the insider transaction. Historical insider transactions for Ladenburg Thalmann Financial Services go as follows:

  • 4-Week # shares bought: 3,477
  • 12-Week # shares bought: 3,477
  • 24-Week # shares bought: 150,929

The average volume for Ladenburg Thalmann Financial Services has been 251,600 shares per day over the past 30 days. Ladenburg Thalmann Financial Services has a market cap of $693.2 million and is part of the financial sector and financial services industry. Shares are down 9.11% year-to-date as of the close of trading on Wednesday.

Ladenburg Thalmann Financial Services Inc., through its subsidiaries, provides brokerage and advisory, investment banking, equity research, institutional sales and trading, asset management, life insurance brokerage, and trust services in the United States. The company has a P/E ratio of 46.8. Currently, there is 1 analyst who rates Ladenburg Thalmann Financial Services a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on LTS - FREE

TheStreet Quant Ratings rates Ladenburg Thalmann Financial Services as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, compelling growth in net income and good cash flow from operations. However, as a counter to these strengths, we find that the company's profit margins have been poor overall. Get the full Ladenburg Thalmann Financial Services Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

null